Age Does Not Adversely Influence Outcomes among Patients Older than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS).
Participation in clinical trials is recommended for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are treated with intensive induction therapy, but enrollment is often challenging.
Post-transplant relapse remains a major cause of treatment failure in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Understanding of the biology of relapse and response to azacitidine treatment remains limited.
Cancer survivors may develop a second cancer as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and this has been an emerging problem for acute promyelocytic leukemia (APL) patients in complete remission (CR).
MDS, sAML, NGS, somatic mutation.
There is an ongoing effort towards shifting care to the outpatient setting following intensive chemotherapy for high-grade myeloid neoplasms, which is medically and logistically challenging for healthcare professionals, patients and caregivers. We hypothesize that in-home ( “telemonitoring”) devices which record vital signs, not previously tested in AML, may facilitate this approach. In this pilot study, we assessed how these devices can be integrated into the outpatient care of AML/MDS patients.
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Umang Patel, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Keyur P. Patel The classification and risk stratification of myeloid neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, myelodysplastic syndromes/myeloproliferative neoplasms, and myeloproliferative neoplasms, have increasingly been guided by molecular genetic abnormalities. Gene expression analysis and next-generation sequencing have led to the ever increasing discovery of somatic gene mutations in myeloid neoplasms. Mutations have been ide...
Conclusion The study participants treated with inpatient, induction chemotherapy experienced statistically significant improvement in their quality of life at 1 month. The outpatient, nonintensive study participants had stable quality of life at 1 month. Micro-Abstract The results of the present pilot study can be used to counsel older patients with acute myeloid leukemia and high-risk myelodysplastic syndrome regarding treatment choices that will align with their goals for their quality of life. Future studies are needed with a larger and more diverse patient sample to address whether the more intensive treatment approach...
This article is protected by copyright. All rights reserved. PMID: 28685821 [PubMed - as supplied by publisher]
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with high-risk hematologic malignancies [1,2]. Common indications for HCT in adults include acute myelogenous leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, lymphoma, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, and certain solid tumors .
We present a case of B-ALL after PCM which does not appear to show a clonal relationship with the original PCM suggesting a treatment related B-ALL. Graphical abstract